NCT02482311 - Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

January 25, 2018

Study Completion Date

August 22, 2019

Conditions

Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

Interventions

DRUG

AZD 1775

"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.~AZD1775 should be taken approximately 2 hours before or 2 hours after food."

Trial Locations (16)

19104

Research Site, Philadelphia

28204

Research Site, Charlotte

29605

Research Site, Greenville

33905

Research Site, Fort Myers

37203

Research Site, Nashville

46202

Research Site, Indianapolis

48201

Research Site, Detroit

53226

Research Site, Milwaukee

72703

Research Site, Fayetteville

73104

Research Site, Oklahoma City

77030

Research Site, Houston

90048

Research Site, West Hollywood

94143

Research Site, San Francisco

T6G 1Z2

Research Site, Edmonton

V5Z 4E6

Research Site, Vancouver

M5G 2M9

Research Site, Toronto